AHA 22: SPYRAL HTN-ON MED: Renal Denervation in Patients with Hypertension

Published: 24 Nov 2022

  • Views:

    Views Icon 304
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

In this insightful interview, Dr David Kandzari (Piedmont Heart Institute, Atlanta, US) joins us to outline the 6-month primary findings of an extension study of the SPYRAL HTN-ON MED Trial (NCT02439775). 

SPYRAL HTN aimed to determine the safety and effectiveness of Symplicity Spyral™ multi-electrode renal denervation system (Medtronic) in patients with hypertension and cardiovascular diseases as compared to a sham procedure. This extension trial aims to determine the long-term outcomes of this trial. 

This trial demonstrated that despite a significant reduction in Office BP and Win Ratio favoring RDN vs Sham, the primary efficacy endpoint was not met for 24-hr ABPM at 6 months.

Access our full AHA 22 Scientific Coverage here.  

Recorded remotely from Atlanta, 2022.

Interviewer: Mirjam Boros
Video Specialist: Oliver Miles